The significant EPS beat and strong revenue growth, coupled with key regulatory and clinical milestones, suggest improving commercial traction. The extended cash runway reduces near-term dilution risk. Monitor Q1 2026 results for sustained growth and updates on the FemBloc pivotal trial enrollment.
Price Chart
Executive Summary
Femasys reported full-year 2025 revenue of $2.29M, up 40.8% YoY, with a net loss per share of $0.47, significantly better than the consensus loss of $0.85. The company highlighted clinical progress, including initiation of the FDA pivotal trial for FemBloc and a $12M financing that extends cash runway into Q3 2026.
Key Financial Metrics
Key Facts
- Revenue for 2025 was $2,293,313, a 40.8% increase from $1,629,108 in 2024, driven by FemBloc sales.
- Net loss per share was $0.47, a significant improvement from $0.85 in 2024 and a substantial beat versus consensus of $-0.85.
- Cash and cash equivalents were $9.3M as of December 31, 2025, sufficient to fund operations into Q3 2026.
- Key milestones: Initiation of the FDA pivotal trial for FemBloc, FDA 510(k) clearance for FemVue Controlled, and a new CPT code for FemaSeed.
Financial Impact
Revenue up 40.8% YoY; EPS loss narrowed by 44.7% YoY and beat consensus by 88.9%.
Risk Factors
- The company remains in a pre-revenue, clinical-stage phase with a history of net losses.
- Future capital raises could lead to shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-012346 |
| Document: ef20069346_8k.htm | 0001140361-26-012346 |
| Document: 0001140361-26-012346-index-headers.html | 0001140361-26-012346 |
| Document: 0001140361-26-012346-index.html | 0001140361-26-012346 |
| Document: 0001140361-26-012346.txt | 0001140361-26-012346 |
| 8-K Data (Synthetic) | 0001140361-26-012346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.41 (−15.57%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.41 (−18.73%) |
Sep 29, 2026 27d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.41 (+32.54%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.41 (+34.72%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.41 (−34.72%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.41 (−40.00%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.41 (+46.99%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.41 (−80.25%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.41 (−81.48%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.41 (−82.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers